AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04856007
Drug: Dapagliflozin/metformin XR FDC 5/500 mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
Trial: NCT04856007
Drug: Dapagliflozin/metformin XR FDC 10/1000 mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
Trial: NCT04856007
Drug: Dapagliflozin 5 mg + Metformin 500 mg XR
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
Trial: NCT04856007
Drug: Dapagliflozin 10 mg + Metformin 1000 mg XR
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
Trial: NCT05982938
Drug: Danicopan
RxNorm normalized name: Danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 150 mg danicopan three times per day (TID) orally as an add-on to a background C5i therapy (SOLIRIS® or ULTOMIRIS®). Participants may be dose-escalated to 200 mg TID based on safety and clinical effect.
Trial: NCT06237569
Drug: Application of ketamine and midazolam or ketamine alone to patients undergoing cesarean section under spinal anesthesia
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single dose of 0.5 mg/kg IV diluted to 5 ml with 0.9% saline was planned to be administered simultaneously to the Ketamine Group (GROUP 1), ketamine and midazolam within 5 minutes after the newborn umbilical cord was clamped (Group 2). After midazolam 0.03 mg/kg is given, a single dose IV bolus of 0.5 mg/kg diluted to 5 ml with 0.9% saline will be administered.~Patients experience dizziness, hallucinations, nausea, headache, vomiting, diplopia and blurred vision, the time until the first analgesic request; Depression parameters will be evaluated with the Edinburgh Postpartum Depression Scale (EPDS) in all patients before cesarean section and at the 1st, 2nd and 4th weeks after birth.
Trial: NCT06565494
Drug: midomafetamine (MDMA)-Assisted Therapy
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment consists 3 Preparation sessions followed by 3 Experimental sessions at 4-week intervals; after each Experimental session, 3 weekly Integration sessions will be conducted. For the first Experimental Session, the dose of MDMA is 80 mg; for the second and third Experimental Sessions, the dose of MDMA is 120 mg. For all three Experimental sessions, a supplemental dose of 50% of the initial dose will be available. The Preparation, Experimental, and Integration Sessions will involve psychotherapy developed specifically for this trial and population.
Trial: NCT05446857
Drug: Glecaprevir / Pibrentasvir Pill
RxNorm normalized name: glecaprevir / pibrentasvir Pill
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
Trial: NCT04667312
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab
Trial: NCT06181084
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05189977
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (tablet, oral ): 40 mg QD Day 3 and Day 21~Intervention 1 is a single dose of prazosin administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state.
Trial: NCT05189977
Drug: Prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prazosin (tablet, oral): 1 mg QD Day 2 and Day 20~Intervention 2 is a single dose of propranolol administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state.
Trial: NCT00018135
Drug: aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00018135
Drug: Sevelamer
RxNorm normalized name: Sevelamer
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05253573
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
Trial: NCT05416580
Drug: UDCA (Ursodeoxycholic acid)
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
Trial: NCT05416580
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.
Trial: NCT04836273
Drug: Dasiglucagon
RxNorm normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abdominal s.c. self-administration 120 µg of dasiglucagon when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
Trial: NCT06328556
Drug: botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use.
Trial: NCT05978544
Drug: Itolizumab
RxNorm normalized name: Itolizumab
DrugBank: Itolizumab (DB16207)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients to be treated with Itolizumab.
Trial: NCT06471205
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.
Trial: NCT06471205
Drug: PD-1 Monoclonal Antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks (Q3W).
Trial: NCT00000945
Drug: Cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000945
Drug: Probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05684861
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: systemic isotretinoin was given to all 90 patients , dose was prescribed according to weight for 3 months
Trial: NCT05000671
Drug: STC314 injection or Placebo(rate=58.3 mg/hr)
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
Trial: NCT05000671
Drug: STC314 injection or Placebo(rate=87.5 mg/hr)
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
Trial: NCT06392659
Drug: VX-993
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for Oral Administration.
Trial: NCT06392659
Drug: Gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets for Oral Administration.
Trial: NCT06392659
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules for Oral Administration.
Trial: NCT06392659
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution for Oral Administration.
Trial: NCT00000918
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000918
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000918
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000918
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00000918
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000918
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000918
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000918
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000918
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000918
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06464718
Drug: Fortibone
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [Cortilone]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were given daily sachet containing 5g of Bio active collagen peptides (Fortibone). Electrolyte mix containing 500 mg calcium as calcium lactate, 4 MCg calcitriol and selenised yeast rich in vitamin D3 (400IU) (Colabone®, Vivapharm SA).
Trial: NCT06464718
Drug: Chewable Tablet
RxNorm normalized name: Chewable Tablet
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcium compound containing 25 g calcium carbonate (500mg elemental calcium) and vitamin D3 400IU taken daily
Trial: NCT05565729
Drug: Levocetirizine
RxNorm normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06575010
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL Liposomal bupivacaine (Exparel) will be given in the shoulder block prior to surgery
Trial: NCT06575010
Drug: Bupivacaine Hcl 0.5% Inj
RxNorm normalized name: BUPIVACAINE HCL 0.5% INJ
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.75% bupivacaine will be given in the shoulder block prior to surgery
Trial: NCT06575010
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg Dexamethasone will be given in the shoulder block prior to surgery
Trial: NCT05345613
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Submucosal injection of standard solution including TXA during EMR procedure
Trial: NCT05345613
Drug: Standard
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of standard solution
Trial: NCT06577233
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10cc of 0.25% Bupivacaine Hydrochloride will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery
Trial: NCT06480539
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nocturnal administration of dexmedetomidine (0.2-1.0 mcg/kg/h) during the first night after surgery. Dexmedetomidine infusion, not preceded by a bolus administration, will be started at 0.4 mcg/kg/h in the intervention group at 8 p.m. the day of surgery. Dexmedetomidine infusion will be titrated every 30 minutes with 0.1 mcg/kg/h steps until a RASS of -1 to -3 (drowsy, light to moderate sedation) is reached. The infusion will be discontinued at 6 a.m. the next morning.
Trial: NCT06574763
Drug: RC48/Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RC48, 2.5mg/kg, iv, Q3W Carboplatin, AUC 5, iv, D1, Q3W
Trial: NCT05069220
Drug: 18F-MFBG
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with neuroendocrine malignancies receive 2-4 MBq/kg of 18F-MFBG intravenously followed by PET/CT after 60min of injection.
Trial: NCT05069220
Drug: 68Ga-Dotatate
RxNorm normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with malignant PPGL and NB receive intravenously 68Ga-Dotatate followed by PET/CT after 40min of injection.
Trial: NCT06024174
Drug: BMS-986466
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06024174
Drug: Adagrasib
RxNorm normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06024174
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05280444
Drug: Idarubicin Hydrochloride for Injection
RxNorm normalized name: Idarubicin Hydrochloride
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of idarubicin is 10 mg and the maximum tolerated dose is 20 mg. Idarubicin is first dissolved in water for injection to make a solvent of 2mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents.
Trial: NCT05129865
Drug: LYT-300
RxNorm normalized name: LYT-200
DrugBank: LYT-200 (DB18179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A prodrug of allopregnanolone, a small molecule drug
Trial: NCT05663073
Drug: Irbesartan/Amlodipine FDC
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan/Amlodipine FDC
Trial: NCT05663073
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Co-administration of Irbesartan and Amlodipine
Trial: NCT05663073
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Co-administration of Irbesartan and Amlodipine
Trial: NCT06200103
Drug: Lutetium Lu 177 Vipivotide Tetraxetan
RxNorm normalized name: lutetium Lu 177 vipivotide tetraxetan
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00511745
Drug: Rabeprazol
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT06059261
Drug: Envafolimab and recombinant human endostatin combined with chemoradiotherapy
RxNorm normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment phase: Envafolimab administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 3 cycles, cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles, gemcitabine was administered by intravenous infusion on days 1 and 8 of each cycle at 1 g/m2 every 3 weeks for 3 cycles, recombinant human endostatin was administered on day 1 every 3 weeks at 210 mg for 3 cycles. Concurrent treatment phase: Cisplatin was administered by intravenous infusion on day 1 of each cycle at 100mg/m2 every 3 weeks for 2 cycles. Adjuvant treatment Phase: Envafolimab was administered on day 1 every 3 weeks at 300 mg for 8 cycles as a subcutaneous injection. Intensity-modulated radiotherapy: 69.96Gy/33fractions/7 weeks,5 fractions/week, 1 fraction/day.
Trial: NCT05258279
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion Q3W
Trial: NCT05258279
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral capsule once daily
Trial: NCT05258279
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion Q3W
Trial: NCT05258279
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion Q3W
Trial: NCT06510270
Drug: Dapagliflozin 10 mg once daily
RxNorm normalized name: lisinopril
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg once daily will be given to all patients in symptomstic heart failure group
Trial: NCT05899842
Drug: Protein pump inhibitor therapy systematically
RxNorm normalized name: Protein C (coagulation inhibitor)
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30mg once per day
Trial: NCT05025644
Drug: Pre and post-CPB Drug: Dobutamine Hydrochloride
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Pre-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) until a PG ≥ 50mmHg is achieved (DBT peak dose). The DBT peak dose (DBT-pd) will be recorded.~* Post-CPB provocation test at the DBT-pd achieved preoperatively.
Trial: NCT05025644
Drug: Post-CPB Drug: Dobutamine Hydrochloride
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Pre-CPB no intervention will be required.~* Post-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) or until postoperative provocable PG is \>16 mmHg.
Trial: NCT05422378
Drug: STP705
RxNorm normalized name: STP705 (small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2))
DrugBank: Cotsiranib (DB18404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.
Trial: NCT05003310
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib (2 mg) is administered daily during the period.
Trial: NCT04959981
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT04959981
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT05879250
Drug: STAT3 Inhibitor WP1066
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06063070
Drug: Fluzoparib Capsules
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT06063070
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injectable solution